X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7830) 7830
Newsletter (32) 32
Magazine Article (25) 25
Book Chapter (17) 17
Newspaper Article (4) 4
Dissertation (3) 3
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6152) 6152
antifungal agents - therapeutic use (4350) 4350
fluconazole (4296) 4296
fluconazole - therapeutic use (3662) 3662
male (3129) 3129
female (2975) 2975
adult (2229) 2229
middle aged (1906) 1906
microbiology (1796) 1796
infectious diseases (1735) 1735
candidiasis - drug therapy (1550) 1550
pharmacology & pharmacy (1510) 1510
antifungal agents - pharmacology (1409) 1409
amphotericin b - therapeutic use (1233) 1233
aged (1226) 1226
amphotericin-b (1140) 1140
microbial sensitivity tests (1136) 1136
treatment outcome (1085) 1085
antifungal agents (1042) 1042
antifungal agents - administration & dosage (997) 997
infections (969) 969
animals (951) 951
fluconazole - pharmacology (948) 948
itraconazole (915) 915
candidiasis (835) 835
epidemiology (805) 805
voriconazole (781) 781
adolescent (772) 772
fluconazole - administration & dosage (768) 768
mycology (743) 743
risk factors (717) 717
immunology (715) 715
mycoses - drug therapy (702) 702
mycoses (688) 688
candida - drug effects (680) 680
candidiasis - microbiology (670) 670
health aspects (660) 660
candida (659) 659
therapy (635) 635
amphotericin b (627) 627
candida albicans - drug effects (618) 618
retrospective studies (606) 606
infection (580) 580
candida - isolation & purification (568) 568
mortality (553) 553
child (546) 546
fungal-infections (534) 534
drug resistance, fungal (524) 524
fungal infections (522) 522
candida albicans (517) 517
itraconazole - therapeutic use (508) 508
drug therapy, combination (505) 505
cryptococcosis - drug therapy (495) 495
triazoles - therapeutic use (493) 493
antifungal agents - adverse effects (489) 489
dermatology (479) 479
administration, oral (477) 477
resistance (463) 463
drug therapy (458) 458
risk-factors (456) 456
medicine, general & internal (455) 455
susceptibility (452) 452
albicans (451) 451
prophylaxis (447) 447
aids (445) 445
aids-related opportunistic infections - drug therapy (433) 433
care and treatment (432) 432
candidemia (430) 430
mycoses - prevention & control (430) 430
analysis (425) 425
mice (423) 423
pharmacokinetics (417) 417
infant, newborn (410) 410
fungi (407) 407
aged, 80 and over (405) 405
meningitis (399) 399
research (390) 390
double-blind (382) 382
immunocompromised host (381) 381
transplantation (381) 381
prospective studies (377) 377
diagnosis (373) 373
antifungals (365) 365
pediatrics (364) 364
caspofungin (360) 360
young adult (349) 349
antifungal agents - pharmacokinetics (348) 348
management (346) 346
invasive candidiasis (341) 341
research article (336) 336
fluconazole - adverse effects (335) 335
in-vitro (333) 333
candidiasis, oral - drug therapy (332) 332
ketoconazole (329) 329
child, preschool (328) 328
aspergillosis (327) 327
fungemia - drug therapy (323) 323
infant (321) 321
meningitis, cryptococcal - drug therapy (318) 318
echinocandins (314) 314
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7349) 7349
Spanish (145) 145
French (125) 125
German (107) 107
Japanese (90) 90
Russian (31) 31
Chinese (29) 29
Italian (29) 29
Portuguese (19) 19
Polish (17) 17
Bulgarian (12) 12
Turkish (10) 10
Dutch (7) 7
Danish (5) 5
Korean (3) 3
Hebrew (2) 2
Hungarian (2) 2
Romanian (2) 2
Czech (1) 1
Lithuanian (1) 1
Slovak (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2017, Volume 102, Issue 8, pp. 3050 - 3055
Context: Delayed thyrotropin (TSH) elevation (dTSH) is defined as elevated TSH at the second neonatal screening (after normal TSH levels at the initial... 
THYROID-STIMULATING HORMONE | ENDOCRINOLOGY & METABOLISM | THYROTROPIN | Cefotaxime - therapeutic use | Ibuprofen - therapeutic use | Multivariate Analysis | Humans | Male | Neonatal Screening | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Furosemide - therapeutic use | Intensive Care Units, Neonatal | Time Factors | Female | Retrospective Studies | Infant, Newborn | Thyrotropin - blood | Dopamine - therapeutic use | Hypoglycemic Agents - therapeutic use | Sympathomimetics - therapeutic use | Infant, Low Birth Weight | Erythrocyte Transfusion | Pneumothorax - epidemiology | Risk Factors | Hypothyroidism - diagnosis | Respiration, Artificial | Cesarean Section | Ductus Arteriosus, Patent - epidemiology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Vancomycin - therapeutic use | Infant, Premature | Diuretics - therapeutic use | Hypothyroidism - blood | Insulin - therapeutic use | Neonates | Intensive care | Cefotaxime | Pathogenesis | Erythrocytes | Vancomycin | Multivariate analysis | Risk factors | Red blood cells | Ibuprofen | Cesarean section | Thyroid | Pneumothorax | Dopamine | Low-birth-weight | Fluconazole | Blood cells | Risk analysis | Insulin | Patients | Furosemide | Screening | Thyroid-stimulating hormone | Pituitary | Ventilation | Birth weight | Health risk assessment
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2016, Volume 2016, Issue 5, p. CD004685
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 2004, Volume 5, Issue 6, pp. 417 - 422
Journal Article
Journal Article
Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 7, pp. CD005647 - CD005647
Background Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of... 
HIV Infections | HIV/AIDS | Acute Disease | Drug Administration Schedule | Fluconazole | Other complications/co‐morbidities: treatment | Acetazolamide | Induction Chemotherapy | Infectious disease | Treatment | Opportunistic infections: prophylaxis & treatment | Amphotericin B | Meningitis, Cryptococcal | HIV | Flucytosine | Antifungal Agents | Developing Countries | Intracranial Hypertension | Drug Therapy, Combination | Network Meta‐Analysis | Medicine General & Introductory Medical Sciences | Health Resources | HIV Infections [complications] | Health Resources [supply & distribution] | Flucytosine [supply & distribution; therapeutic use] | Humans | ANTIRETROVIRAL THERAPY | Fluconazole [supply & distribution; therapeutic use] | MAINTENANCE THERAPY | MEDICINE, GENERAL & INTERNAL | Adult | Intracranial Hypertension [drug therapy] | Antifungal Agents [supply & distribution; therapeutic use] | Antihypertensive Agents [adverse effects] | RANDOMIZED-TRIAL | FUNGAL BURDEN | PLUS FLUCYTOSINE | Meningitis, Cryptococcal [drug therapy] | Amphotericin B [supply & distribution; therapeutic use] | HIGH-DOSE FLUCONAZOLE | Acetazolamide [adverse effects] | DOUBLE-BLIND | INFECTED PATIENTS | PLACEBO-CONTROLLED TRIAL | AMPHOTERICIN-B DEOXYCHOLATE | Amphotericin B - supply & distribution | Meningitis, Cryptococcal - drug therapy | Fluconazole - supply & distribution | Induction Chemotherapy - methods | Health Resources - supply & distribution | Fluconazole - therapeutic use | Antifungal Agents - supply & distribution | Antifungal Agents - therapeutic use | Meningitis, Cryptococcal - mortality | Intracranial Hypertension - drug therapy | Acetazolamide - adverse effects | Flucytosine - therapeutic use | HIV Infections - complications | Network Meta-Analysis | Amphotericin B - therapeutic use | Flucytosine - supply & distribution | Index Medicus
Journal Article
Cochrane library, ISSN 1469-493X, 2014, Volume 2020, Issue 6, p. CD004707
Background Opportunistic fungal infections are a major cause of morbidity and mortality in neutropenic cancer patients and antifungal therapy is used both... 
'ORPHAN' TOPICS CURRENTLY BEING ADDRESSED | Infections in neutropenic cancer patients | Fluconazole | Mycoses | Neoplasms | Randomized Controlled Trials as Topic | Opportunistic Infections | Pyrimidines | Infections in neutropenic patients | Amphotericin B | Triazoles | Aspergillosis | Voriconazole | Antifungal Agents | Liposomes | Medicine General & Introductory Medical Sciences | General cancer treatments | Neutropenia | Cancer | Amphotericin B [adverse effects; therapeutic use] | Humans | Aspergillosis [drug therapy] | Opportunistic Infections [drug therapy] | PREVENTION | EMPIRICAL ANTIFUNGAL THERAPY | Triazoles [adverse effects; therapeutic use] | Mycoses [drug therapy] | FUNGAL-INFECTIONS | TRIAL | Neutropenia [drug therapy; microbiology] | MEDICINE, GENERAL & INTERNAL | Antifungal Agents [adverse effects; therapeutic use] | Pyrimidines [adverse effects; therapeutic use] | Fluconazole [adverse effects; therapeutic use] | DOUBLE-BLIND | Neoplasms [complications] | Triazoles - adverse effects | Antifungal Agents - adverse effects | Fluconazole - adverse effects | Opportunistic Infections - mortality | Fluconazole - therapeutic use | Neutropenia - drug therapy | Antifungal Agents - therapeutic use | Opportunistic Infections - microbiology | Amphotericin B - adverse effects | Neoplasms - complications | Pyrimidines - therapeutic use | Neutropenia - microbiology | Opportunistic Infections - drug therapy | Mycoses - drug therapy | Neutropenia - mortality | Pyrimidines - adverse effects | Mycoses - mortality | Amphotericin B - therapeutic use | Aspergillosis - drug therapy | Triazoles - therapeutic use
Journal Article
Journal Article